“This is a novel strategy for treating neurodegenerative diseases, and it underscores the importance of brain cholesterol,” said Chitra Mandyam, associate professor at TSRI and co-first author of the study with Jan M. Schilling of UC San Diego and the VA.
Senior author Brian Head, a research scientist with the VA and associate professor at UC San Diego, added, “By bringing back this protein, you’re actually bringing cholesterol back to the cell membrane, which is very important for forming new synaptic contacts.”
The study, published recently online ahead of print in the journal Biological Psychiatry, focuses on a specific membrane protein called caveolin-1 (Cav-1) and expands scientists’ understanding of neuroplasticity, the ability of neural pathways to grow in response to new stimuli.
Previous work by Head’s group at the VA and at UC San Diego had shown that raising Cav-1 levels supported healthy “rafts” of cholesterol involved in neuron growth and cell signaling; however, it wasn’t clear if this new growth actually improved brain function or memory.
To find out, the researchers delivered Cav-1 directly into a region of the brain known as the hippocampus in adult and “aged” mice. The hippocampus is a structure thought to participate in the formation of contextual memories—for example, if one remembers a past picnic when later visiting a park.
In addition to improved neuron growth, treated mice demonstrated better retrieval of contextual memories—they froze in place, an indication of fear, when placed in a location where they’d once received small electric shocks.
Mandyam and Head believe that this type of gene therapy may be a path toward treating age-related memory loss. The researchers are now testing this gene therapy in mouse models of Alzheimer’s disease and expanding it to possibly treat injuries such as spinal cord injury and traumatic brain injury. Mandyam said this new understanding of Cav-1 and neuroplasticity could also be relevant to memory loss due to alcohol and drug use.
“We’re very interested in studying whether we can manipulate Cav-1 in other areas of the brain,” Mandyam said.
In addition to Mandyam, Schilling and Head, authors of the study, “Neuron-targeted caveolin-1 improves molecular signaling, plasticity and behavior dependent on the hippocampus in adult and aged mice,” were Junji Egawa, Ingrid R. Niesman, Sarah E. Kellerhals, Anna R. Busija, Edmund Posadas, Grace C. Grogman, Jamie W. Chang, Victoria B. Risbrough, David M. Roth, Piyush M. Patel and Hemal H. Patel of UC San Diego and the VA; Weihua Cui of UC San Diego, Capital Medical University and the VA; and Miranda C. Staples of TSRI.
For more information on the paper, see http://www.biologicalpsychiatryjournal.com/article/S0006-3223(15)00817-3/abstract
This study was supported by the Department of Veterans Affairs (grants BX001225, BX000783 and BX001963) and the National Institutes of Health (grants NS073653, HL091071, HL107200, GM085179 and DA034140).
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates—work toward their next discoveries. The institute’s graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
# # #
Office of Communications